I work in the financial services industry and am a long-time investor in the biotech sector. Harvard JD. Expert on option valuation and accounting for executive compensation. Moderator of the Biotech Valuation thread at SIlicon Investor, which has had over 30,000 posts since its inception: http://siliconinvestor.advfn.com/subject.aspx?subjectid=26145 See Seeking Alpha's policy on anonymous authors: http://seekingalpha.com/article/69847-seeking-alpha-policy-on-anonymous-authorship
I'm an oncology PhD student at the University of California San Francisco (UCSF) in the Biomedical Sciences Program. I also enjoy long term, fundamental, biotech investing. My favorite investments MDVN, FPRX, and XNCR.
Capital Markets consultant and active investor in the emerging life science space. Tenured futures trader. Able to provide access to a pool of investors and traders throughout the US and UK. ProActive Capital, a capital markets advisory firm that makes direct investments and provides advisory services into public and private life science companies. Areas of focus include; capital introduction, shareholder management, communications and investor outreach.
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).